About
Dr. Tran, Abzyme Therapeutics co-founder, CSO of Abzyme Therapeutics LLC. He has a PhD…
Activity
2K followers
-
Hiep Tran shared thisAt Abzyme Therapeutics, we focus on developing camelid-derived modular antibodies to support our partners in the development of bispecific antibodies. To rapidly generate VHH antibodies, we combine multi-antigen llama immunization, yeast surface display immune libraries, and single-cell FACS sorting to isolate modular antibodies with optimized attributes. https://lnkd.in/e9ha7MynBispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightBispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
-
Hiep Tran reposted thisHiep Tran reposted thisThe complement cascade is essential for immune defense — tagging pathogens, triggering inflammation, and forming the membrane attack complex (MAC). But its power goes both ways. Dysregulation is linked to autoimmunity, neurodegeneration, and more — making it a key target for diagnostics and drug development. Explore the full pathway, key effector proteins like C3a and C5a, and curated antibodies, proteins, and ELISAs. 👉 https://lnkd.in/e_n_dZej #ComplementSystem #InnateImmunity #Immunology #Inflammation #MAC #C3a #C5a #AntibodiesOnline #ResearchTools
-
Hiep Tran shared thisRoyersford, PA, October 29, 2024 – Abzyme Therapeutics LLC, a biotechnology company focused on developing innovative antibody-based therapies, announced today that it has been awarded U.S. Patent No. 12,116,411 for its groundbreaking anti-CD3 antibody technology. This patent solidifies Abzyme’s intellectual property position in the field of therapeutic antibody development and underscores its commitment to advancing novel cancer treatments. The newly patented antibodies exhibit a novel pH-dependent binding profile, demonstrating high affinity to human CD3 at acidic pH conditions found in solid tumors. This specificity minimizes off-target binding to normal tissues, a major challenge in antibody-based therapies. By leveraging the acidic tumor microenvironment, Abzyme’s antibodies improves tumor targeting and while reducing toxicity. For further information and interest in licensing these novel anti-CD3 antibodies, please contact: Abzyme Therapeutics LLC Stephen Manobianco, MBA. Director of Business Development Phone: 610-205-9650 E-mail: manobianco@abzymetx.com
-
Hiep Tran posted thisWe at Abzyme Therapeutics and our collaborators, Drs. Yoonjee Park of The University of Cincinnati and Bärbel Rohrer of The Medical School of South Carolina are very excited with a recent SBIR phase II award from the National Eye Institute with a total funding $1,657,994 for 2 years. This project entitled “Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases” is aimed at developing a potent and long-acting camelid-derived multi-specific antibody targeting both VEGF and extracellular MMP inducer (Emmperin/Basigin/CD147) to prevent choroidal neovascularization. The phase II award is the continuation of a successful prior SBIR phase I research grant awarded by NIH/NEI. According to BrightFocus Foundation, nearly 20 million adults in the U.S. have some form of age-related macular degeneration (AMD). The risk of getting advanced AMD increases from 2% for those ages 50-59, to nearly 30% for those over the age of 75.
-
Hiep Tran shared thisAs a hands-on user of Rockland reagents and services to characterize our antibody candidates, I look forward to this webinar to learn more about their capacities.Hiep Tran shared this🔬 Webinar Alert! Join us for "Reagents, Tools, and Custom Services For Characterizing Biologic Drug Potency," hosted with Promega North America. Dive into the world of biologic drugs as we explore the critical role of immunogenicity in drug development. Gain valuable insights into characterizing and quantifying monoclonal antibody therapeutics. 📅 Date: December 6, 2023 🕒 Time: 10:00-11:00 AM #BiologicDrugs #Webinar #DrugDevelopment #Immunogenicity #BiotechInnovation
-
Hiep Tran shared thisHiep Tran shared thisEnhancing Progressive Multiple Sclerosis Treatment with Abzyme Antibodies In his recently published book, Stephen Hauser, the director of the Weill Institute for Neurosciences and a neurology professor at the University of California, San Francisco, writes “The immune system, designed to protect us against invading microbes, misidentifies nerve cells and their myelin coverings as foreign. This leads to an autoimmune attack — the body turning against itself.” In addition to exploring the genetic roots of MS, Hauser and his team identified the critical role of B cells in attacking nerve cells, leading to the development of immunosuppressive drugs that target and destroy the B cells, thus reducing inflammation, slowing down nerve damage, and easing symptoms. These B-cell therapies were the first to be effective in treating progressive MS and have been enormously beneficial for those living with the disease. Instead of killing all antibody-producing B cells, Abzyme developed antibodies that block antibody-mediated complement activation. In the MS mouse model, we have shown that our antibodies Improve the neurological disability caused by multiplesclerosis. For more information, please contact manobianco@abzymetx.com #multiplesclerosis #MS #abzymetx #antibodies #neurodegenerativediseasesBook Review: A Physician's Quest to Treat Multiple SclerosisBook Review: A Physician's Quest to Treat Multiple Sclerosis
-
Hiep Tran shared thisHiep Tran shared thisAre you looking for a new antibody supplier or starting a new project? Rockland is currently running a promotion where you can purchase our trial-size antibodies for as low as $99. We have 700+ primary antibodies available in sample size. With our trial sizes, you can easily test your antibody or perform pre-screening before committing to a larger quantity purchase. No matter what size antibody you are buying, you can expect to have full access to Rockland's world-class technical and customer support.
-
Hiep Tran reacted on thisHiep Tran reacted on thisAlways great to welcome Gettysburg College back to Rockland. As proud alumni, our COO Richard Smith, CEO James (Jim) Fendrick, and VP Ashley Cush enjoy staying connected with the Gettysburg community. It was a pleasure to host Billy Ferrell and a group of students for a tour and conversation about the work happening here at Rockland Immunochemicals. We’re grateful for opportunities like this to share what we do and to keep strengthening the relationship between Rockland and Gettysburg College. Looking forward to continuing these visits in the years ahead.
-
Hiep Tran reacted on thisHiep Tran reacted on thisToday I’m honored to step into the role of Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals. Reflecting on my Vertex journey, I’m grateful for the extraordinary teamwork, scientific innovation, and meaningful impact we have delivered together for patients. It’s been a privilege to grow with such a talented group of colleagues, united by our commitment to scientific excellence under the incredible leadership of David Altshuler. Thank you, David, for your guidance, support and inspiration over the past decade. As I take on this new challenge, I remain as passionate as ever about advancing our mission and building on the legacy of success that we've created together. I look forward to leading and supporting our remarkable Drug Discovery and Research teams as we continue to push the boundaries of science and develop transformational medicines for the patients we serve. The future holds great promise, and I am excited to continue this journey.
-
Hiep Tran liked thisHiep Tran liked thisRockland is heading to Budapest for this year’s Oligonucleotide Therapeutics Society (OTS) Annual Meeting, taking place October 19–22. Our team will be onsite sharing insights into antibody-based tools for oligonucleotide detection and analysis, including two new ModDetect™ posters: 📰 Detection and Quantification of PS-Modified ASO in Biological Matrices using ModDetect™ Panel 📰 Antibody-based Analytical Assays for the Localization, Quantification, and Trafficking of Oligonucleotide Therapeutic Drugs in Serum, Cells, and Tissues Whether you’re exploring analytical workflows, custom antibody generation, or ModDetect™ Panels, we’d love to connect and discuss your next project. 👉 Schedule a meeting: https://lnkd.in/dgX2Uc43 #OTS2025 #OligonucleotideTherapeutics #RNAtherapeutics #ModDetect #AntibodyBasedAssays #RocklandImmunochemicals
-
Hiep Tran liked thisHiep Tran liked thisLast Friday, I stood among some of the most accomplished technology leaders in the world, peers who continue to push the boundaries of innovation and leadership across industries. It was both unexpected and deeply humbling. I was honored to be named the winner of the 2025 Global CIO of the Year Award, recognized through the #PhillyORBIEAwards, among an incredible field of world-class technology executives. This recognition is a meaningful milestone and a reminder to always lead with humility, stay grounded, and stay focused on impact. Congratulations to all the finalists and winners across every category, and thank you to the Inspire Leadership Network, PhillyCIO, the judges, and sponsors for fostering a community that celebrates technology leadership and transformation. Special thanks to • Anna Burdett, Blair Whitcomb and Joshua Beeman. This award belongs to ACR Technology Services (#ACRTS) as much as it belongs to me. It reflects the dedication and excellence of an incredible organization that turns vision into execution every day. To Sean Flaville and Daniel McAdams, thank you for your support and for representing the IT organization in person beside me. To ACR (AmerCareRoyal), our CEO Scott Milberg, and the leadership team, thank you for trusting me to lead technology transformation during such a pivotal time in our growth. A special thank you to Paul Patek , our CFO, for believing in my vision from the start and giving me the space to execute it. His trust has been pivotal in helping drive transformation forward. I am deeply grateful for the colleagues, mentors, and peers whose support and challenge have shaped the leader I continue to become. And to my wife, kids, and parents, you are what inspires me to do what I do every day. Your belief keeps me grounded and driven. Recognition like this isn’t the goal. Impact is. Grateful for the people, the purpose, and the journey, and the blessings that continue to guide it forward. The best chapters are still being written. - #PhillyCIO #PhillyORBIEAwards #CIO #InspireCIO #Titan100 #TechnologyLeadership #BusinessTransformation #EnterpriseTechnology #OperationalExcellence #LeadingTransformation #DrivingChange #StrategicLeadership #ExecutionExcellence #ACRTS
-
Hiep Tran liked thisHiep Tran liked thisWe are excited to announce key milestones across our pipeline: JK07 advances in heart failure and pulmonary hypertension, and JK06 is on track to debut first-in-human results at ESMO 2025 https://lnkd.in/ee6X2Bxw. #SalubrisBio #JK06 #JK07Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical ProgramsSalubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs
-
Hiep Tran liked thisHiep Tran liked thisI'm so grateful to BioBuzz - Greater Philadelphia, Angela Fernandez-Iglesias, Ph.D. & Chris Frew for the chance to join Sharon Hilgen Willis, Julia Sable and Sima Singadia Kulkarni in a thoughtful conversation on self-advocacy, networking, and career journeys in biotech. The discussion was dynamic and left me feeling inspired and energized to be part of this community. Public speaking isn’t usually my comfort zone, but stepping up for this event reminded me how worthwhile it is to push past those limits. Special thanks to Kelly Zaccheo, Ph.D. and Greg Chrest for your support at the event!
-
Hiep Tran liked thisHiep Tran liked thisSince RFK Jr, Makary, and Trump now hold press conferences based on a correlation, I think that they should immediately announce a warning on organic food sales!! The rise in organic food sales correlates DIRECTLY with the rise in the rates of autism and it does so in much stronger fashion than acetaminophen or vaccines! Thus, HHS and the FDA should issue an immediate “advisory” and have a major pres conference!! Yes…that’s is exactly how foolish you all sound and continue to sound, when you defend these “policies” or this administration’s behavior.
Experience
-
-
-
-
-
-
-
Education
-
St. Petersburg State University, Russian Federation
-
-
-
-
-
-
-
-
-
-
-
Languages
-
English
-
-
Russian
-
-
French
-
-
Vietnamese
-
Other similar profiles
Explore more posts
-
ISEF - Israel Scholarship Education Foundation
The fight against cancer just got smarter. Researchers at Ben-Gurion University of the Negev including ISEF PhD fellow Abd Alkader Yassin, have developed nanotech-enhanced CAR T-cell therapy that reprograms the immune system to target cancer more precisely and persistently. By creating artificial surfaces that mimic how T-cells naturally activate, the team dramatically improved cell endurance and potency. Their work, supported by global institutions and published in Advanced Materials, could soon scale for real-world treatment. We're beyond proud to see ISEF scholars, from diverse social and ethnic backgrounds, not just imagining the future but helping shape it. Congratulations, Abd! Abd’s role in this breakthrough reflects the very heart of ISEF’s mission: enabling brilliant, committed scholars in Israel to lead discoveries that change lives. Read full article here: https://lnkd.in/d2XVkCi2 #isefcommunity #car_t #phdimpact #cancerinnovation #bengurionuniversity #nanotechresearch #tcellbreakthrough #immunotherapy #advancedmaterials #isef
-
Life Sciences | Bar-Ilan University
From fundamental RNA biology to clinical innovation. In this video, Prof. shulamit Michaes, Faculty of Life Sciences at Bar-Ilan University and recipient of the Israel Prize in Life Sciences, shares her latest breakthrough. Supported by a grant from the Ministry of Innovation, Science and Technology, Government of Israel, her team developed a topical therapeutic for leishmaniasis, a parasitic disease caused by Leishmania. The treatment is expected to enter clinical evaluation at Tel Aviv Medical Center (Ichilov) in the near future. #LifeSciences #TranslationalResearch #Leishmaniasis #BarIlanUniversity
-
Ynet Global
Reichman University to host third annual Lema’anchem medical conference, drawing over 800 experts to explore breakthroughs in regenerative medicine, personalized care, and the growing role of artificial intelligence in shaping the future of healthcare. *** Notable speakers include Prof. Uriel Reichman, host of the conference and founding president and chairman of Reichman University; Prof. Ran Balicer, chief innovation officer at Clalit Health Services; Clalit chairperson Maj. Gen. (res.) Yochanan Locker; Prof. Eli Sprecher, CEO of Tel Aviv Sourasky Medical Center Center; Prof. Jacob Hanna of the Weizmann Institute of Science; Prof. Eran Meshorer of the The Hebrew University of Jerusalem; Prof. Ayal Hendel of Bar-Ilan University; and Prof. Irit Avivi, head of the Division of Hematology at Sourasky. The event will be hosted by Israeli television personality Guy Zo-Aretz. https://bit.ly/43Q8DUu #UrielReichman #ReichmanUniverstiy #StemCells #ClalistHealthCare #SouraskyMedicalCenter #HebrewUniversity #healthcarenews #ynetGlobal
-
Hemostasis Today
Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network - Shai Shen-Orr Allen Institute for Immunology | RIKEN Research Center for Allergy and Immunology | Sustainable Sciences Institute (SSI) | Technion - Israel Institute of Technology | Yale University https://lnkd.in/evsp_5Bs #AllenInstituteForImmunology #HumanFunctionalGenomicsProject #CenterForHumanImmunologyAtStanfordUniversity #DZNE #Health #Hematology #Hemostasis #HemostasisToday #YaleUniversity #Medicine #HIPScientificPartnerNetwork #HumanImmunomeProject #Immunology #HypoVaxGlobal #RIKENResearchCenterForAllergyAndImmunology #SustainableSciencesInstitute #SwarmLearningConsortium #WEHI #ImmuneSystem #TechnionIsraelInstituteOfTechnology #Thrombosis
-
Elee Shimshoni
⚕️ Today, the biomed community lost a a pioneer of cancer #immunotherapy. Prof. Zelig Eshhar spearheaded the development of #CART cell technology in the early 90's at the Weizmann Institute of Science. The basis of this technology involves engineering T-cells to posses a chimeric receptor that incorporates properties from antibodies for increased specificity and efficacy, which allows the T-cells to effectively recognize transformed cells and eliminate them. Over the last two decades numerous CAR-T therapies have emerged, and have changed the outlook for blood cancers forever. Recently, the FDA even relaxed regulatory boundaries for healthcare systems to deliver CAR-T treatments to patients. This will allow more patients to get access to these life-saving therapies, currently produced by big pharmaceutical companies like BMS and Novartis. These same principles are also being applied for solid tumors, incorporating gene editing technologies for neo-antigen recognition, but there is still a road ahead. 🕯️ May Zelig Eshhar's memory be a blessing. His legacy certainly lives on.
-
Derhsing Lai , Ph.D.
Happy Halloween 🎃 📢Vincogen Unveils VincoAI De Novo Agonists and Biologics for Next-Generation Weight Loss Therapies, Targeting 8 Key Metabolic Proteins in Silico [October 31, 2025, Pennsylvania] – Vincogen, a leader in AI-driven de novo drug discovery, today announced a significant advancement in its VincoAI platform, focusing on the identification and development of novel peptides, VH nanoantibody, and AI-de novo agonists for weight loss. The company's innovative in silico approach has successfully targeted 8 critical proteins identified as pivotal in metabolic pathways governing appetite, energy expenditure, and fat metabolism, representing a multi-billion-dollar global market opportunity. The VincoAI platform has meticulously mapped the intricate interactions within key metabolic pathways, identifying specific vulnerabilities and points of intervention across the following high-impact targets: 1.) GLP1R & GIPR (Dual Agonism): Building on the success of gold-standard obesity treatments, Vincogen is developing compounds that enhance satiety and insulin sensitivity through dual agonism. 2.) GDF15: Targeting this appetite-suppressing cytokine, a major focus for pharmaceutical innovation, to reduce food intake. 3.) GPR75: A novel anti-obesity receptor where knockout studies have demonstrated conferred leanness, indicating significant therapeutic potential. 4.) PPARG: Modulating this receptor to optimize fat storage and improve insulin sensitivity. 5.) OREXIN-1: Focusing on pathways that regulate energy expenditure and arousal, crucial for sustainable weight management. 6.) SGLT2: Developing mechanisms to reduce body weight through enhanced glycosuria, a clinically validated approach. 7.) NRF2: Activating this pathway to boost mitochondrial activity and reduce fat mass, promoting a healthier metabolic state. 8.) ACVR2B: Activin/myostatin receptors, it may reduce fat mass while preserving muscle mass. 🌍 Market Potential The global weight loss and weight management market is projected to reach over $300 billion in the coming years, underscoring the immense unmet need for effective and sustainable treatments. Vincogen is actively seeking partnerships to advance these promising programs through preclinical and clinical development. 🚀 Why VH Nanoantibodies? 1.) 10x smaller than conventional antibodies (12-15 kDa vs. 150 kDa) 2.) Superior CNS, BBB penetration 3.) Reduced immunogenicity 4.) Access to hidden epitopes ⚡ The AI Advantage: Traditional discovery: Screen hundreds of molecules over years VincoAI platform: Evaluate millions of virtual candidates in weeks About VincoAI: Computational therapeutics company pioneering AI-driven biologics for neurological diseases. Powered by Vincogen's GenAI platform with HDOCK/HPEPDOCK validation. Forward-looking statement: Computational predictions don't guarantee experimental efficacy. Results may vary. Please contact Alexander G. Lai at alexl@vincogen.com for more information.
1 Comment
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content